Developing new biopharmaceutical products for infectious diseases
Official title: Preclinical Services for Biopharmaceutical Product Development
Funded at International AIDS Vaccine Initiative · NIH-10934767 · Data updated 2026-11-12
This study is all about helping scientists create new medicines, like antibodies and proteins, to treat infections, so that patients can eventually benefit from these innovative therapies in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $3,796 |
| NIH project number | 75N93023D00010-0-759302300001-2 |
| Project ID | NIH-10934767 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals affected by infectious diseases who may be eligible for new biopharmaceutical therapies.
✕Less likely to help
Patients with non-infectious diseases or those not eligible for biopharmaceutical interventions may not receive benefits from this research.
What this research studies
This research focuses on providing essential services to support the preclinical development of biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and nucleic acid-based vectors like small interfering RNA. The program aims to advance translational research by offering product development planning, assay development, and regulatory support to ensure effective treatments for infectious diseases. Patients may benefit from innovative therapies that emerge from this preclinical work, which is crucial for bringing new treatments to clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and effective treatments for infectious diseases.
How similar studies have gone: Previous research in biopharmaceutical development has shown success in creating effective treatments, indicating that this approach is promising.
Where this research is happening
-
International AIDS Vaccine Initiative
New York, United States Active
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Developing vaccines and biologics for infectious diseases
This study is working on creating and improving vaccines to help protect people from infectious diseases like the flu and Nipah virus, so that patients can have better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Developing and producing new vaccines for infectious diseases.
This study is all about creating and testing new vaccines to help protect people from infectious diseases, including those that could come from bioterrorism or drug-resistant germs, so that patients can have better options for staying healthy.
-
New mRNA vaccines to prevent tuberculosis for adolescents and adults
A new mRNA vaccine approach aims to prevent TB in teens and adults and reduce transmission, using advanced vaccine technology.
-
New mRNA Vaccines for Tuberculosis
This research explores new mRNA vaccine technology to protect adolescents and adults from tuberculosis, a serious lung infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.